App-Quantinova.ai

Long-term (156-week) improvements in dactylitis and enthesitis with apremilast inpsoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database

Dafna D Gladman - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Apremilast

Cardiovascular risk in clinical subtypes of psoriatic arthritis

Neelam Hassan - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials

Nick Barkham - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study

Iain McInnes - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses

Iain McInnes - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

secukinumab

Improvement of psoriatic nail disease in psoriatic arthritis patients treated with adalimumab: results of an observational cohort up to 36 months

Neil McHugh - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Adalimumab

Correlating plasma cytokine levels with right heart catheterisation parameters in systemic sclerosis-related pulmonary arterial hypertension

Chup Hei Ho - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Interferon Gamma

Copers and catastrophisers: coping strategies are associated with patient-reported assessment of the severity and impact of Raynaud’s phenomenon in systemic sclerosis

John Pauling - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Raynaud syndrome

N/A

Comparing classification criteria for systemic sclerosis incorporating thermographic parameters

Joanne Manning - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Raynaud syndrome

N/A

Clinical features and prevalence of double antibody positivity in a large cohort of systemic sclerosis patients

Alper Sari - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

A lost-to-follow-up autoantibody for the diagnosis of autoimmune disease: prevalence and clinical characteristics of anti-NOR90/hUBF positive patients

Christos Koutsianas - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Proton pump inhibitor use is associated with calcinosis in systemic sclerosis

Lauren V Host - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Esomeprazole

Correlation of the American College of Rheumatology provisional composite response index in systemic sclerosis with serum biomarkers of fibrogenesis in an observational cohort

Giuseppina Abignano - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Microvascular flow assessed by dynamic optical coherence tomography: first non-invasive quantitative outcome measure of microvascular disease in systemic sclerosis

Giuseppina Abignano - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Raynaud syndrome

N/A

Normalisation of the American College of Rheumatology provisional composite response index in systemic sclerosis numerator for baseline data offers a measure of magnitude of response: results from a real-life observational study

Giuseppina Abignano - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Anti-TNF induces sarcoidosis: a peculiar paradox

Surabhi Wig - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Regionalexperience of igg4-related disease

Mark Lloyd - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immunoglobulin G4 related disease

N/A

Musculoskeletal symptoms represent a significant burden for adults with cystic fibrosis

Elizabeth A Clarke - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Prevalence of periodontitis in patients with rheumatoid arthritis and systemic lupus erythematosus

Marco Orlandi - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

An unusual case of unilateral myositis

Ruth Smith - British Society for Rheumatology (BSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Myositis

N/A

Filters

45280 Abstracts